PET concerns in bevacizumab treatment (multiple letters)

Nature Medicine

Volumn 10, Issue 6, 2004, Pages 561-

  Goessl, Carsten ^a   Grozdanovic, Zarko ^b   Willett, Christopher G ^c   Duda, Daniel ^d   Fischman, Alan ^d   Jain, Rakesh K ^d  

^a NOVARTIS PHARMA AG   (Switzerland)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL;

CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DRUG CROSS REACTIVITY; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN; LETTER; LONG TERM CARE; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECTUM CANCER;

EID: 2942705791     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0604-561a     Document Type: Letter

References (0)